UK markets open in 17 minutes
  • NIKKEI 225

    27,011.33
    -120.01 (-0.44%)
     
  • HANG SENG

    24,251.58
    +7.97 (+0.03%)
     
  • CRUDE OIL

    85.51
    -0.09 (-0.11%)
     
  • GOLD FUTURES

    1,846.90
    -5.60 (-0.30%)
     
  • DOW

    34,297.73
    -66.77 (-0.19%)
     
  • BTC-GBP

    27,654.73
    +840.83 (+3.14%)
     
  • CMC Crypto 200

    848.20
    +27.62 (+3.37%)
     
  • ^IXIC

    13,539.29
    -315.83 (-2.28%)
     
  • ^FTAS

    4,139.47
    +40.31 (+0.98%)
     

SHOP APOTHEKE EUROPE: STRONG ACCELERATION OF SALES AND CUSTOMER GROWTH IN Q4.

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • SAEYY
  • SHPPF

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Development of Sales/Preliminary Results
11.01.2022 / 07:00
The issuer is solely responsible for the content of this announcement.

SHOP APOTHEKE EUROPE: STRONG ACCELERATION OF SALES AND CUSTOMER GROWTH IN Q4.


Sevenum, 11 January 2022. According to preliminary and unaudited calculations, SHOP APOTHEKE EUROPE's sales rose by 9.5% to EUR 1.06 billion. In the fourth quarter, sales amounted to EUR 287.8 million, an increase of 8.7% compared to previous year's strong fourth quarter. The group gained 1.6 million active customers during the year, thereof 0.5 million in the fourth quarter. The total number of active customers reached 7.9 million by the end of 2021.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE: "We are looking back on a very strong fourth quarter. We successfully returned to our previous growth path. In 2021, we made significant progress in implementing SHOP APOTHEKE EUROPE's strategy to become a customer-centric e-pharmacy platform: This includes the expansion of our digital health services, the roll-out of our same-day delivery service SHOP APOTHEKE NOW! to Germany's metropolitan areas and the opening of our new next-generation logistics centre. Most recently, in December, we took a major leap in broadening our product range by adding 20,000 health-care related products through the launch of our own marketplace in Germany. Last but not least, we have been ready for e-Rx in Germany since last summer. We successfully processed the first e-Rx prescriptions from customers since then."

In the full year 2021, the largest segment by sales, DACH, which includes SHOP APOTHEKE EUROPE's business activities in Germany, Austria and Switzerland, grew by 3.9% compared to 2020. Sales increased to EUR 847 million compared to EUR 815.4 million in the previous year; Rx sales were down 34.7% to EUR 143.3 million, everything-but-Rx on the contrary grew by 18.1% to 703.7 million. In the fourth quarter, DACH sales were EUR 228.7 million (previous year: 223.7 million). In the International segment (France, Belgium, Italy and the Netherlands), SHOP APOTHEKE EUROPE expanded sales by 39.6% to EUR 213.1 million in 2021 (EUR 152.7 million in the previous year) and by 44.1% to EUR 59.1 million in the fourth quarter.

CFO Jasper Eenhorst comments: "We achieved our full-year guidance of increasing total sales by around 10% thanks to an impressive 21% growth spurt from Q3 to Q4. Our propositions and marketing activities have successfully increased our total base of active customers by 0.5 million to 7.9 million. Our new logistics centre processed the orders flawlessly. We are ready for 2022."

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the full annual report for the financial year 2021 on 2 March 2022.
 

About SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, 7.9 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany, the company will further improve the customer experience with a focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.

PRESS CONTACTS.

Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: presse@shop-apotheke.com

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: carmen.herkenrath@shop-apotheke.com

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: presse@shop-apotheke.com


11.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

SHOP APOTHEKE EUROPE N.V.

Dirk Hartogweg 14

5928 LV Venlo

Netherlands

Phone:

0800 - 200 800 300

Fax:

0800 - 90 70 90 20

E-mail:

carmen.herkenrath@shop-apotheke.com

Internet:

www.shop-apotheke-europe.com

ISIN:

NL0012044747, DE000A19Y072

WKN:

A2AR94, A19Y07

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1266960


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting